The Spectra Optia(R) Apheresis System from Terumo Blood and Cell Technologies in combination with UVA PIT system can now be used to provide extracorporeal photopheresis immunotherapy The company is ...
LAKEWOOD, Colo.--(BUSINESS WIRE)--Terumo BCT announced today that the Spectra Optia system mononuclear cell (MNC) collection protocol is now cleared by the U.S. Food and Drug Administration (FDA) and ...
Terumo's Spectra Optia® Apheresis System Terumo's Spectra Optia® Apheresis System LAKEWOOD, Colo., U.S., and SANTA ROSA, Calif., U.S., July 27, 2022 (GLOBE NEWSWIRE) -- Acute kidney injury (AKI) and ...
LAKEWOOD, Colorado, April 6, 2017 /PRNewswire/ -- Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, today announced that the Spectra Optia ® Apheresis ...
Terumo Blood and Cell Technologies presents data on collection efficiency process with Spectra Optia(R) Apheresis System at major conferences Lakewood, Colorado, US, May 25, 2023 – Terumo Blood and ...
In a significant step toward expanding treatment access for people with rare and chronic diseases in Latin America (LATAM), Terumo Blood and Cell Technologies (Terumo BCT), announced that its Spectra ...
This resource has been developed to provide practical information and advice relating to NICE medical technologies guidance on Spectra Optia for automatic red blood cell exchange in people with sickle ...
LAKEWOOD, Colorado, April 6, 2017 /PRNewswire/ --Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, today announced that the SpectraOptia ® Apheresis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results